GENB
Generate Biomedicines, Inc.
$17.41
+0.91 (+5.52%)
At close · Jul 2
Market Cap
$2.23B
Shares
128,192,484
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.41
Open$16.52
Day$16.48–17.60
52W$11.00–18.18
Avg vol 30d1.0M
Short int4.5M · 3.5% float · 4.8d
Short vol66%
Last earningsMay 7, 2026
DataFeb 2026–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Strong Buy
◦
50 / 200-day cross
no cross
+
Price vs 50-day avg
+24% above
◦
RSI (14)
67 · neutral
+
MACD trend
positive
+
52-week position
89% · near high
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50/200-day averages unavailable
+
Institutional flow
+58 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
3.55% of float · ▲ +11.3% MoM · 4.8 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
58 holders — 13F breadth
Fundamentals
Limited data
Not enough data for a confident read.
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
no cross
Neutral
Price vs 50-day avg
+24% above
Bullish
RSI (14)
67 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
89% · near high
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+58 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.55% of float · ▲ +11.3% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
58 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $11
Now $17 · 89%
52-wk high $18
vs 50-day avg +24%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GENB
this stock
Generate Biomedicines, Inc.
|
$2.23B | — | — | — | 3.5% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GENB | +6.0% | +34.9% | — | +3.2% | — |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +4.6% | +36.1% | — | +3.5% | — |
Key facts
CIK
2100782
CUSIP
370920100